EMHA Team visits London for MTIS: This upcoming September, EMHA team will be visiting the British capital city of London in order to participate in the MTIS congress organized by Migraine Trust. EMHA will be participating in the activities held during the Congress such as communications meetings, active participation on roundtables and of course an […]
EMHA Team visits London Read More »
Novartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its- kind treatment specifically designed for migraine prevention Jul 30, 2018 New Aimovig Medication Approved Novartis announced today that the European Commission (EC) approved Aimovig® (erenumab) for the prevention of migraine in adults experiencing four or more migraine days per month.
New Aimovig Medication Approved Read More »
Why is migraine still a big mystery to science Very common especially in women, these intense headaches are still a great medical mystery whose causes are not enlightened. Very common especially in women, these intense headaches are still a great medical mystery whose causes are not enlightened. Migraines are always related to a “simple headache”,
The science of migraine Read More »
11.3% of Spanish teenagers suffer from migraine headaches Migraine and teenagers The journal Cephalalgia – the scientific publication of the International Society of Headaches – has just published a study by members of the Headache Study Group of the Spanish Society of Neurology (SEN) of the Vall D’Hebron University Hospital, whose Objective was to evaluate
Migraine and teenagers Read More »
Effective behavioral treatments for migraine are being eschewed by a significant number of sufferers, according to a new study led by headache researchers at NYU School of Medicine. Researchers found that about half of migraine patients who were referred by a headache center for specific behavioral treatment did not follow through with therapy. This occurred
Why are migraine patients skipping effective behavioral treatments? Read More »
How to take care of your diet if you suffer migraine 30th MAY 2018 If we pay attention to what we eat, we can contribute to keeping headaches as far away from our lives as possible. If you have migraine, you probably know that maintaining a healthy lifestyle and respecting food and sleep schedules are
Diet and migraine Read More »
Friday, June 1, 2018, at 15:45 Novartis has announced that the European Medicines Agency (EMA) Committee on Human Use Medicines (CHMP) has recommended Aimovig (erenumab) approval to prevent migraine in adults suffering at least 4 days of migraine per month. The World Health Organization (WHO) has mentioned migraine as one of the top ten causes
Novartis’ Migraine prevention therapy is closer to being approved Read More »
First monoclonal antibody therapy for prevention of Migraine Aimovig recommended for marketing authorization 01/06/2018 The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Aimovig (erenumab), the first human monoclonal antibody therapy for prevention of migraine. Aimovig belongs to a new class of medicines that work by blocking the activity
First monoclonal antibody therapy for prevention of migraine Read More »
Recurrent, troublesome occipital pain associated with muscular tension is known as Arnold’s neuralgia, a strange condition. The condition of peripheral nerves can produce the pain of varying intensity as a reflex mechanism, depending on the degree of damage being considered. Some anatomical locations are often associated with these syndromes, with the exception of the occipital
Arnold Neuralgia/Recurrent occipital pain cause Read More »
Cluster headache: Galcanezumab Prevention of episodic cluster headache: Primary endpoint achieved in Phase 3 study 16/05/2018 Eli Lilly and Company announced that Galcanezumab met with the primary endpoint in a Phase 3 trial of episodic cluster headache patients, the statistically significant differences in reducing headache attacks. In weekly clusters compared to placebo during the weeks
Cluster headache: Galcanezumab Read More »
